Cardio-vascular diseases

Cardio-vascular diseases

The cardio-vascular diseases represent a worldwide public health concern

 

They are the first cause of mortality in the world before cancer.They were responsible for 17 million deaths in 2008 and they are expected to cause more than 24 million deaths in 2030, this number dramatically being correlated with ageing increase (World Health Organization) – cf WHO


The current global market for cardio-vascular in vitro diagnostic is highly dynamic (USD 5.0 Bn in 2016 with a CAGR of +8%); the “emergency room” sub-segment of this market is estimated to reach USD2Bn in 2016 (IVS Market Reports).


The direct and indirect costs associated to these diseases are considerable (€192 bn in Europe; $450 bn in US in 2008). Emergency rooms are expensive and saturated. They are capital and labor intensive; Delayed diagnostic due to the use of automates and long processes delays the initiation of the treatment. It increases the like hood of patients long term disabilities and associated costs (expense, medication expenses…)


The lack of robust, rapid and quantitative portable diagnostics leads to mortality, patients disabilities and generates various costs for insurers and health care providers. In that context, physicians and healthcare providers are in dire need of cost and time efficiency.